Please wait...
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Yes
76% of Medicare Part D and Medicare Advantage plans cover this drug.It depends. Which coverage stage are you in? Click on a tab below…
$42 – $395
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your incruse ellipta prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Incruse Ellipta (umeclidinium) is an anticholinergic that works by relaxing muscles in the airways to improve breathing.
Incruse Ellipta is used to prevent airflow obstruction and reduce flare-ups in adults with COPD (chronic obstructive pulmonary disease, including bronchitis and emphysema.
Incruse Ellipta is for use only in people with COPD and should not be used to treat asthma.
You should not use Incruse Ellipta if you are allergic to umeclidinium or have a severe allergy to milk proteins.
Incruse Ellipta is not a rescue medicine. It will not work fast enough to treat a bronchospasm attack. Use only a fast acting inhalation medicine for an attack.
Seek medical attention if your breathing problems do not improve, or if your symptoms get worse quickly.
You should not use Incruse Ellipta if you are allergic to umeclidinium, or if you have:
a severe allergy to milk proteins.
To make sure Incruse Ellipta is safe for you, tell your doctor if you have:
glaucoma;
heart disease;
an enlarged prostate; or
urination problems.
Tell your doctor if you are pregnant or breastfeeding.
Incruse Ellipta is not approved for use by anyone younger than 18 years old.
Use Incruse Ellipta exactly as it was prescribed for you. Follow all directions on your prescription label and read all medication guides or instruction sheets.
Incruse Ellipta is a powder that comes with a special inhaler device preloaded with blister packs containing measured doses of the medicine. The device opens and loads a blister of powdered medicine each time you use the inhaler. Follow the patient instructions provided with the inhaler device.
The usual dose is 1 inhalation per day. Use the medicine at the same time each day, and not more than once in a 24-hour period.
Incruse Ellipta is not a rescue medicine. It will not work fast enough to treat a bronchospasm attack. Use only a fast acting inhalation medicine for an attack. Tell your doctor if any of your medicines seem to stop working as well in controlling your COPD.
Do not stop using this medicine without your doctor's advice, even if you feel fine.
Do not try to clean or take apart the inhaler device. Always use the new inhaler device provided with your refill.
Store at room temperature away from moisture, heat, and light. Keep the inhaler device in the sealed foil tray until ready to start using it.
Throw the inhaler away 6 weeks after opening, or when the dose indicator shows a zero (whichever comes first).
Usual Adult Dose for Chronic Obstructive Pulmonary Disease -- Maintenance:
1 inhalation (62.5 mcg) orally once a day
Maximum dose: 1 inhalation every 24 hours
Use: Treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema
Use the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not use two doses at one time. Do not use more than once in a 24-hour period.
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
Do not use a second inhaled bronchodilator that contains aclidinium, arformoterol, indacaterol, olodaterol, salmeterol, tiotropium, or vilanterol.
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
Get emergency medical help if you have signs of an allergic reaction to Incruse Ellipta: hives, rash, severe itching; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
wheezing, choking, or other breathing problems after using this medicine;
blurred vision, nausea, vomiting, eye pain or redness, or seeing halos or bright colors around lights; or
painful or difficult urination, or urinating more often.
Common Incruse Ellipta side effects may include:
cold symptoms such as stuffy nose, sneezing, sore throat, cough;
fast or irregular heartbeats;
bruising, darkened skin;
mouth pain, tooth pain;
muscle or joint pain;
stomach pain; or
altered sense of taste.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all your other medicines, especially:
atropine;
medicine to treat depression, anxiety, mood disorders, or mental illness;
cold or allergy medicine (Benadryl and others);
medicine to treat Parkinson's disease;
medicine to treat stomach problems, motion sickness, or irritable bowel syndrome;
medicine to treat overactive bladder; or
another bronchodilator medication.
This list is not complete. Other drugs may interact with umeclidinium, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Incruse Ellipta only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Incruse Ellipta (www.drugs.com/incruse-ellipta.html).
Note: This document contains side effect information about umeclidinium. Some of the dosage forms listed on this page may not apply to the brand name Incruse Ellipta.
Applies to umeclidinium: inhalation powder
Along with its needed effects, umeclidinium (the active ingredient contained in Incruse Ellipta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking umeclidinium:
Less common
Incidence not known
Some side effects of umeclidinium may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
Applies to umeclidinium: inhalation powder
Common (1% to 10%): Tachycardia, hypertension, sinus tachycardia (greater than or equal to 1%)
Uncommon (0.1% to 1%): Atrial fibrillation, idioventricular rhythm, supraventricular tachycardia, supraventricular extrasystoles
Common (1% to 10%): Rash
Common (1% to 10%): Upper abdominal pain, toothache, dyspepsia (greater or equal to 1%), diarrhea (greater or equal to 1%), nausea (greater or equal to 1%)
Uncommon (0.1% to 1%): Constipation, dry mouth
Common (1% to 10%): Urinary tract infection
Frequency not reported: Worsening of urinary retention
Common (1% to 10%): Arthralgia, myalgia, back pain, neck pain (greater or equal to 1%), pain in extremity (greater or equal to 1%)
Common (1% to 10%): Headache, sinus headache (greater or equal to 1%), dizziness (greater or equal to 1%)
Uncommon (0.1% to 1%): Dysgeusia
Common (1% to 10%): Contusion, vertigo (greater or equal to 1%)
Common (1% to 10%): Depression (greater or equal to 1%)
Common (1% to 10%): Nasopharyngitis, upper respiratory tract infection, viral respiratory tract infection, cough, sinusitis, pneumonia (greater than or equal to 1%), lower respiratory tract infection (greater than or equal to 1%), rhinitis (greater than or equal to 1%), oropharyngeal pain (greater than or equal to 1%)
Uncommon (0.1% to 1%): Pharyngitis
Frequency not reported: Worsening of narrow-angle glaucoma (eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema)
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Incruse Ellipta (www.drugs.com/incruse-ellipta.html).
June 25, 2020
June 23, 2020
June 22, 2020
June 18, 2020
June 17, 2020
June 4, 2020
